6. Other Receivables

In April 2024, entinostat received marketing approval in China. As a result the Company recorded $3.5 million of milestone revenue in 2024. As of June 30, 2025, the Company recorded a $3.6 million milestone receivable related to achieved milestones under the license agreement with Eddingpharm. Full payment of the receivable is expected by December 2026.